EAM
SLN

Eventide Asset Management’s Silence Therapeutics SLN Stock Holding History

Eventide Asset Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-640,000
Closed -$4.4M – 255
2024
Q4 		$4.4M Hold
640,000
– – 0.08% 157
2024
Q3 		$11.6M Buy
+640,000
New +$11.9M 0.2% 115

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Eventide Asset Management's SLN Position: Q1 2025 in Review

Eventide Asset Management sold out of Silence Therapeutics (SLN) in Q1 2025, closing a stake of 640,000 shares — an estimated $4.4M sold.

Eventide Asset Management first reported a position in SLN in Q3 2024 and held it in 2 quarters. The position peaked at $11.6M in Q3 2024. 59 funds tracked by Wall St. Rank hold SLN as of Q1 2025.

  • Eventide Asset Management reported no remaining Silence Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Eventide Asset Management sold 640,000 Silence Therapeutics shares in Q1 2025, an estimated $4.4M.
  • Eventide Asset Management first reported a position in Silence Therapeutics in Q3 2024 and held it in 2 quarters.
  • Eventide Asset Management's Silence Therapeutics position peaked at $11.6M in Q3 2024.
  • 59 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2025.

Based on Eventide Asset Management's 13F filing for Q1 2025, filed 15 May 2025.